First clinical experience with an adjunctive hemoperfusion device designed specifically to remove β2-microglobulin in hemodialysis

Contributions to Nephrology

Volumn 133, Issue , 2001, Pages 166-173

  Ronco, Claudio ^a,b   Brendolan, Alessandra ^b   Winchester, James F ^b   Golds, Ellen ^b   Clemmer, Jonathan ^b   Polaschegg, Hans Dietrich ^c   Muller, Thomas E ^b   Davankov, Vadim ^b   Tsyurupa, Maria ^b   Pavlova, Ludmila ^b   Pavlov, Mikhail ^b   La Greca, Giuseppe ^b   Levin, Nathan W ^a  

^a RENAL RESEARCH INSTITUTE   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

^c Renal Tech International ^*

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; ARTICLE; EQUIPMENT DESIGN; EVALUATION; HEMOPERFUSION; HUMAN; INSTRUMENTATION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; BETA 2-MICROGLOBULIN; EQUIPMENT DESIGN; HEMOPERFUSION; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0035534308     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (14)

1. 2-microglobulin. Biochem Biophys Res Commun 1985;129:701-706.
2. 2-Microglobulin modified with AGE products of the Maillard reaction in dialysis-related amyloidosis; in Maeda K, Shinzato T (eds): Dialysis-Related Amyloidosis. Contrib Nephrol. Basel, Karger, 1995, vol 112, pp 52-64.
3. Drueke TB: Beta-2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000;15(suppl 1): 17-24.
4. 2-microglobulin turnover in dialyzed patients. Kidney Int 1992;42:1434-1443.
5. Leypoldt JK, Cheung AK, Deeter RB: Effect of dialyzer reuse: Dissociation between clearances of small and large solutes. Am J Kidney Dis 1998;32:295-301.
6. Winchester JF, Ratcliffe JG, Carlyle E, Kennedy AC: Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int 1978; 14:74-81.
7. Homma N, Gejyo F, Hasegawa S, Teramura T, Ei I, Maruyama H, Arakawa M: Effects of a new adsorbent column for removing beta-2-microglobulin from circulating blood of dialysis patients; in Maeda K, Shinzato T (eds): Dialysis-Related Amyloidosis. Contrib Nephrol. Basel, Karger, 1995, vol 112, pp 164-171.
8. 2-micro-globulin adsorbent during hemoperfusion with human whole blood. J Am Soc Nephrol 2000;11: 257A.
9. Tan SY, Baillod R, Brown E, Farrington K, Soper C, Percy M, Clutterbuck E, Madhoo S, Pepys MB, Hawkins PN: Clinical, radiological and serum amyloid P component scintigraphic features of beta-2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999;14:1467-1671.
10. Leypoldt JK, Cheung AK, Carrol CE, Stannard D, Pereira BJG, Agodoa LY, Port FK: Effect of dialysis membranes and middle molecule removal of chronic hemodialysis patient survival. Am J Kidney Dis 1999;33:349-355.
11. Brady JA, Potempska A, Ronco C, Yousha E, Muller T, Levin N: Ex vivo cytokine clearance with a new adsorbent material from endotoxin-stimulated whole blood. J Am Soc Nephrol 2000;11: 586A.
12. Lornoy W, Because I, Billiouw JM, Sierens L, Van Melderen P, D'Haenens P: On-line haemodiafiltration. Remarkable removal of beta-2-microglobulin. Long-term clinical results. Nephrol Dial Transplant 2000; 15(suppl 1):49-54.
13. Hoenich NA, Stamp S: Clinical performance of a new high-flux synthetic membrane. Am J Kidney Dis 2000;36:345-352.
14. Ronco C, Brendolan A, Cappelli G, Ballestri M, Inguaggiato P, Fortunato L, Milan M, Pietribiato G, La Greca G: In vitro and in vivo evaluation of a new membrane for hemodialysis. Reference methodology and clinical results. 2. In vivo study. Int J Artif Organs 1999;22:616-624.